{"id":244,"date":"2021-06-15T14:30:18","date_gmt":"2021-06-15T21:30:18","guid":{"rendered":"https:\/\/depts.washington.edu\/efgh\/?page_id=244"},"modified":"2021-10-12T09:43:38","modified_gmt":"2021-10-12T16:43:38","slug":"about-shigella","status":"publish","type":"page","link":"https:\/\/depts.washington.edu\/efgh\/enterics-for-global-health\/about-shigella\/","title":{"rendered":"About Shigella"},"content":{"rendered":"<p><em>Shigella<\/em> is a gram-negative bacteria responsible for an estimated 60,000 deaths each year in children under 5. In low and middle-income countries, nearly one-third of children experience at least an episode of <em>Shigella<\/em>-attributable diarrhea during their first 2 years of life. <em>Shigella<\/em> infection is also associated with linear growth failure, a marker of vulnerability to childhood infection, decreased vaccine efficacy, and lifelong morbidity. The morbidity and mortality attributed to <em>Shigella<\/em> combined with the rise in antimicrobial-resistant <em>Shigella<\/em> infections make this a priority pathogen to prevent.<\/p>\n<p>Several promising <em>Shigella<\/em> vaccines are in development and Phase IIb\/III clinical trials in the target population of children living in low- and middle-income countries are slated to begin as early as 2024. Eventual trials will require a consortium of LMIC sites in settings with a high incidence of <em>Shigella<\/em>-attributed diarrhea, specifically of vaccine-preventable <em>Shigella<\/em> serotypes; a demonstrated track record of following Good Clinical Practice (GCP) standards; high participant retention; and the laboratory capacity to confirm <em>Shigella<\/em> infection. Such preparatory efforts will ensure costly clinical trials do not fail due to insufficient statistical power, high loss to follow-up, or substantial heterogeneity in the diagnostic performance of microbiologic methods for <em>Shigella<\/em> confirmation.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shigella is a gram-negative bacteria responsible for an estimated 60,000 deaths each year in children under 5. In low and middle-income countries, nearly one-third of children experience at least an episode of Shigella-attributable diarrhea during their first 2 years of life. Shigella infection is also associated with linear growth failure, a marker of vulnerability to&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/efgh\/enterics-for-global-health\/about-shigella\/\" aria-label=\"Read more about About Shigella\">Read more<\/a><\/div>\n","protected":false},"author":6,"featured_media":0,"parent":2,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"templates\/template-no-hero.php","meta":{"footnotes":"","_members_access_role":[],"_members_access_error":""},"class_list":["post-244","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/efgh\/wp-json\/wp\/v2\/pages\/244","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/efgh\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/depts.washington.edu\/efgh\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/efgh\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/efgh\/wp-json\/wp\/v2\/comments?post=244"}],"version-history":[{"count":8,"href":"https:\/\/depts.washington.edu\/efgh\/wp-json\/wp\/v2\/pages\/244\/revisions"}],"predecessor-version":[{"id":1265,"href":"https:\/\/depts.washington.edu\/efgh\/wp-json\/wp\/v2\/pages\/244\/revisions\/1265"}],"up":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/efgh\/wp-json\/wp\/v2\/pages\/2"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/efgh\/wp-json\/wp\/v2\/media?parent=244"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}